RxDoctor Payments Data

Misty Poole, MD

Internal Medicine · Vidalia, GANPI 1134358419

Payments from drug & device makers

$3,381in general payments, 2019–2025

Across 223 payments — averaging $15.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$991
  • Pfizer$360
  • Lilly USA, LLC$313
  • AstraZeneca$264
  • AbbVie$180
  • Amgen$176
  • plus $1K from 31 others

What the payments were for

  • Food & beverage$3,33699%
  • Education$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,381 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$251,031
Medicare patients
376
Services billed
4,636

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide217$285,548
MounjaroTirzepatide118$132,229
EliquisApixaban162$124,389
JanuviaSitagliptin Phosphate58$51,978
JardianceEmpagliflozin46$45,234
XifaxanRifaximin12$38,297
Tresiba Flextouch U-200Insulin Degludec26$37,340
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$36,176
FarxigaDapagliflozin Propanediol38$34,685
RybelsusSemaglutide17$31,719
LinzessLinaclotide32$30,912
TrulicityDulaglutide26$26,864
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$26,843
JanumetSitagliptin Phos/Metformin Hcl35$26,557
Tresiba Flextouch U-100Insulin Degludec38$24,531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$991$317,267234 claims
Lilly USA, LLCMounjaro, Trulicity$313$159,093144 claims
PfizerEliquis, Nurtec Odt$360$136,169175 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$51$49,10871 claims
Boehringer IngelheimJardiance$95$45,23446 claims
AstraZenecaFarxiga, Symbicort$264$40,14259 claims
AbbVieLinzess, Synthroid$180$39,790153 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$43$38,29712 claims
Johnson & JohnsonXarelto, Invokana$27$26,63738 claims
Sumitomo Pharma America, Inc.Gemtesa$19$14,98623 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$54$6,719541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Vidalia

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →